Earnings Call · Q3 FY2023·2023-11-02

Q3 23EPS +8.75%·Rev n/aQ2 23EPS +14.67%·Rev n/aQ1 23EPS +3.28%·Rev n/aQ4 22EPS +4.62%·Rev n/a⚠ consensus missing

Syndax Pharmaceuticals Inc SNDX

Sharon Klahre — Head of Investor Relations

Michael Metzger — Chief Executive Officer

Neil Gallagher — Chief Medical Officer

Keith Goldan — Chief Financial Officer

+0.1%1d on move date−0.8% vs SPY3d−1.1%5d−8.8%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more SNDX calls or request research access.

More SNDX calls Browse calls Request research access